



**PHARMACY AND THERAPEUTICS COMMITTEE
MEDICAID MEETING MINUTES
October 26, 2023**

*Attendance: Microsoft Teams Meeting
Rakel Beall-Wilkins, Magellan Health; Connie Chan, Staff/Clinical Pharmacist; Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph’s University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Enterprise Director Clinical Pharmacy programs, Jefferson Health; Merleen Harris-Williams, Medical Director; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Student Intern; Lawrence Jones, Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Christina Le, Pharmacy Student Intern; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Karleen Melody; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

Excused: Justin Bittner, Medical Director; Gary Bledsoe, Staff/Clinical Pharmacist; Kay Chan, Manager Pharmacy Benefit Design and Audits; Demian Elder, Medical Director; Oluwatoyin Fadeyibi, Community Behavior Health; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist

Minutes taken by: Joana Iverson

I. Administrative Update

| TOPIC | DISCUSSION | ACTIONS | RESPONSIBLE PARTY | RESOLVED/PENDING |
|---|--|---|-------------------|----------------------|
| <i>Minutes Review/Approval</i> | <i>D. Dolores presented the minutes from the August 2023 meeting to the Committee for review.</i> | <i>The Committee approved the minutes from our last meeting as presented.</i> | <i>D. Dolores</i> | <i>Resolved</i> |
| <i>Annual Review of Policies & Procedures</i> | <i>D. Dolores reviewed the following Policies & Procedures:</i> <ul style="list-style-type: none"> • <i>Pharmacy Prior Authorization</i> <ul style="list-style-type: none"> ○ <i>Updated to include Inter-rated Reliability process</i> | | <i>D. Dolores</i> | <i>Informational</i> |

| TOPIC | DISCUSSION | ACTIONS | RESPONSIBLE PARTY | RESOLVED/PENDING |
|-------|---|---------|-------------------|------------------|
| | <ul style="list-style-type: none"> • Pharmacy Operations and Responsibilities • Pharmacy Formulary Management • Immediate Need 5 Day and 15 Day • Pharmacy Vendor Management • Drug Utilization Review • Recipient Restriction Program • COVID-19 Emergency Procedure (retiring) | | | |

II. Drug Formulary Review/Update

| TOPIC | DISCUSSION | ACTIONS | RESPONSIBLE PARTY | RESOLVED/PENDING |
|--|---|--|---|------------------|
| Prior Authorization Criteria Review (Non-PDL) | <p>The Committee reviewed the Prior Authorization Criteria (Non-PDL). The Committee approved as presented.</p> <ul style="list-style-type: none"> • Apokyn • Bexarotene gel • Corticotropin Injection Gel • Evryski • Imcivree • Linezolid • Megace ES • Sivextro • Strensiq • Vijoice | The Committee approved as presented. The Prior Authorization Criteria (Non-PDL) will be sent to PARP for approval. | F. Vaisberg S. Ford S. Jackson R. Spencer J. Tran | Resolved |
| Quantity Limit Additions | <p>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Nitrofurantoin Susp 50 Mg/5ml – 40mL per day | The Committee approved as presented. The Quantity Limit Additions will be sent to PARP for approval. | F. Vaisberg | Resolved |
| 2024 DHS Prior Authorization Criteria Review (effective 1/8/2024) | <p>The Committee reviewed the 2024 DHS Prior Authorization Criteria Review. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Androgenic Agents • Antibiotics, GI And Related Agents • Antidepressants, Other • Antihemophilia Agents • Antipsychotics • Antivirals, CMV • Anxiolytics • Bone Density Regulators • CGM Products* • Cytokine And Cam Antagonists | The Committee approved as presented. The 2024 DHS Prior Authorization Criteria Review will be sent to PARP for approval. | F. Vaisberg | Resolved |

| TOPIC | DISCUSSION | ACTIONS | RESPONSIBLE PARTY | RESOLVED/PENDING |
|-------|---|---------|-------------------|------------------|
| | <ul style="list-style-type: none"> • <i>Dupixent</i> • <i>Estrogens</i> • <i>Hepatitis C Agents</i> • <i>Hereditary Angioedema (HAE) Agents</i> • <i>Hypoglycemics, Incretin Mimetics-Enhancers</i> • <i>Immunomodulators, Atopic Dermatitis</i> • <i>Lipotropics, Other</i> • <i>Macular Degeneration Agents</i> • <i>Migraine Prevention Agents</i> • <i>Multiple Sclerosis Agents</i> • <i>Natalizumab</i> • <i>Obesity Treatment Agents</i> • <i>Pituitary Suppressive Agents, LHRH</i> • <i>Sedative Hypnotics</i> • <i>Tubeless Insulin Delivery Devices (new PDL class)</i> | | | |

III. 2024 PDL Updates

| | | | | |
|---|---|---|--------------------|-----------------|
| Drugs moving to NPD Status (NPD drugs require PA) | <p><i>The Committee reviewed and approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Cinvanti Vial</i> • <i>Esbriet Cap</i> • <i>Pirfenidone Tab</i> • <i>Ideelvion</i> • <i>Clonidine ER 0.17 mg Tablet</i> • <i>Valcyte (valganciclovir) Solution</i> • <i>Relenza Inhalation</i> • <i>Glucagon Emergency Kit</i> • <i>Byooviz</i> • <i>Gilenya Cap</i> • <i>Mesalamine Enema Kit</i> | <i>The Committee approved as presented.</i> | <i>F. Vaisberg</i> | <i>Resolved</i> |
| Drugs moving from NPD/Non-PDL Status to PRD Status | <p><i>The Committee reviewed the Drugs moving from NPD/Non-PDL Status to PRD Status. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Belbuca Film</i> • <i>Briviact Tab</i> • <i>Diastat Acudial and Rectal Kit</i> • <i>Clomipramine Cap</i> • <i>Mirtazapine ODT</i> • <i>Vilazodone</i> • <i>Fosaprepitant Vial</i> • <i>Miconazole Solution</i> | <i>The Committee approved as presented. The Drugs moving from NPD/Non-PDL Status to PRD Status will be sent to PARP for approval.</i> | <i>F. Vaisberg</i> | <i>Resolved</i> |

| | | | | |
|--|---|--|--|--|
| | <ul style="list-style-type: none"> • <i>Cetirizine Cap</i> • <i>Cetirizine-D Tab</i> • <i>Desloratadine Tab</i> • <i>Fexofenadine-D Tab</i> • <i>Levocetirizine Solution</i> • <i>Loratadine Chew Tabs</i> • <i>Loratadine-D 12HR Tab</i> • <i>Febuxostat Tablet</i> • <i>Syfovre Vial</i> • <i>Nucala 40mg/ml Syringe</i> • <i>Kesimpta Pen</i> • <i>Exkivity Cap</i> • <i>Lytgobi Tab</i> • <i>Scemblix Tab</i> • <i>Moxifloxacin Drops</i> • <i>Se-Natal 19 Tablet</i> • <i>Qelbree ER (viloxazine) Capsule</i> • <i>Abilify Asimtufii</i> • <i>Valganciclovir Solution</i> • <i>Levalbuterol Nebulizer Vial</i> • <i>Noreth-Ethinyl Estradiol Fe 0.4-0.035 (21)-75 Chewable</i> • <i>Wymzya Fe Chewable</i> • <i>Aurovela 24 Fe</i> • <i>Blisovi 24 Fe</i> • <i>Charlotte 24 Fe Chew</i> • <i>Finzala Chew</i> • <i>Hailey 24 Fe</i> • <i>Junel 24 Fe</i> • <i>Larin 24 Fe</i> • <i>Microgestin 24 Fe</i> • <i>Noreth-Ethinyl Estradiol-Fe 1-0.02(24)-75 Chewable</i> • <i>Tarina 24 Fe</i> • <i>Levono-Ethinyl Estradiol + EE 0.10-0.02 mg + 0.01 mg (3-month)</i> • <i>Vabysmo Vial</i> • <i>Tezspire Pen</i> • <i>Ocrevus Vial</i> • <i>Jaypirca Tab</i> • <i>Mekinist Solution</i> • <i>Vanflyta Tab</i> | | | |
|--|---|--|--|--|

| | | | | |
|--|--|--|---------------------------|------------------------|
| | <ul style="list-style-type: none"> • <i>Zimhi Syringe</i> • <i>Wesnatal DHA Complete Combo Pack</i> • <i>Ermeza (levothyroxine) Solution</i> • <i>Levono-Ethinyl Estradiol + EE 0.15-0.03 mg + 0.01 mg (3-month)</i> • <i>Incruse Ellipta</i> • <i>Adalimumab-fkjp(CF) 50 mg/ml Syringe</i> • <i>Hadlima and Hadlima (CF)</i> • <i>Xeljanz XR</i> • <i>Yusimry (CF)</i> • <i>Linzess 72 mcg Cap</i> • <i>Arnuity Ellipta</i> • <i>Asmanex HFA</i> • <i>Qvar Redihaler</i> • <i>Ozempic</i> • <i>Humulin N</i> • <i>Xigduo XR</i> • <i>Nexletol Tab</i> • <i>Nexlizet Tab</i> • <i>Cimerli Vial</i> • <i>Nucala 100mg/ml Autoinjector</i> • <i>Fingolimod Cap</i> • <i>Calquence Tab</i> • <i>Krazati Tab</i> • <i>Rezlidhia Cap</i> • <i>Zejula Tab</i> • <i>Leuprolide Depot Vial</i> • <i>Lisdexamfetamine Capsule</i> • <i>Austedo XR Tab</i> | | | |
| <p>IV. Specialty Drug Additions</p> | <p><i>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> • <i>Akeega 50/500mg, 100/50mg tablet</i> • <i>Aphexda 62mg injection</i> • <i>Daxxify 100U injection</i> • <i>Elrexifio 44mg/1.1mL, 76mg/1.9mL injection</i> • <i>Gavreto 100mg capsule</i> • <i>Izervay solution 2/0.1mL</i> • <i>Ngenla 24mg/1.2mL, 60mg/1.2mL injection</i> • <i>Ngenla 24/1.2mL, 60/1.2mL injection</i> • <i>Ojjaara 100mg, 150mg, 200mg tablet</i> • <i>Reblozyl 25mg, 75mg injection</i> • <i>Rystiggo injection 280/2ML</i> | <p><i>The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.</i></p> | <p><i>F. Vaisberg</i></p> | <p><i>Resolved</i></p> |

| | | | | |
|---------------------------|---|---|-------------------|-----------------|
| | <ul style="list-style-type: none"> • <i>Sogroya 5mg, 10mg, 15mg tablet</i> • <i>Sohonos 1mg, 1.5mg, 2.5mg, 5mg, 10mg capsule</i> • <i>Talvey 3mg/1.5mL 40mg/mL injection</i> • <i>Veopoz 400mg/20mL injection</i> • <i>Xdemvy drops 0.25%</i> | | | |
| V. New Drug Review | <p><i>J. Steffan presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</i></p> <ul style="list-style-type: none"> • <i>Penbraya (meningococcal groups A, B, C, W, and Y vaccine) Injection</i> • <i>Zilbrysq (zilucoplan) Injection</i> • <i>Xphozah (tenapanor) Tablets</i> • <i>Qlosi (pilocarpine hydrochloride) Ophthalmic Solution - formerly CSF-1</i> • <i>Bimzelx (bimekizumab-bkzx) Injection</i> • <i>Velsipity (etrasimod) Tablets</i> • <i>Tofidence (tocilizumab-bavi) Injection</i> • <i>Rivfloza (nedosiran) Injection</i> • <i>Technegas (technetium Tc 99m carbon) Inhalation Aerosol</i> • <i>Pombiliti (cipaglucoasidase alfa-atga) Lyophilized Powder for Injection</i> • <i>Opfolda (miglustat) Capsules</i> • <i>Ryzumvi (phentolamine mesylate) Ophthalmic Solution - formerly Nyxol</i> • <i>Likmez (metronidazole) Oral Suspension</i> • <i>Exxua (gepirone) Extended-Release Tablets</i> • <i>Ojjaara (momelotinib) Tablets</i> • <i>Aphexda (motixafortide) Lyophilized Powder for Injection</i> • <i>Tyruko (natalizumab-sztn) Injection</i> • <i>Veopoz (pozelimab-bbfg) Injection</i> • <i>Eylea HD (aflibercept) Injection</i> | <i>The Committee approved the New Drug Review as presented and recommended.</i> | <i>J. Steffan</i> | <i>Resolved</i> |

VI. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2024.



11/14/23

Danielle Dolores, Director of Pharmacy Services

Date